SINOVAC and Bogotá Present BogotáBio, Colombia's First Public Vaccine Manufacturing Facility

The company's launch ceremony was led by Sinovac's CEO and Chairman, Mr. Weidong Yin, alongside Bogotá's Mayor, Claudia López.

December 18, 2023, Bogotá, Colombia – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a renowned global provider of bio-pharmaceutical products, announced today its partnership with the District of Bogotá in establishing BogotáBio, a company focused on vaccine and biologics development and production, marking a significant milestone in the country's pursuit of health sovereignty.

The launch ceremony presided over by Sinovac's Chairman, President & CEO , Mr. Weidong Yin, and Bogotá's Mayor, Claudia López, marked the official start of this pioneering enterprise in Colombia. The company's incorporation was formalized, unveiling its corporate identity, symbolizing a steadfast commitment to public health and Colombia's technological and industrial advancement.

Mr. Yin noted that the COVID-19 pandemic has made all countries fully realize the importance of vaccines for national security and people's health and Bogotá Government made the choice of SINOVAC as a strategic partner came after evaluating proposals from 15 biopharmaceutical companies around the world. Bogotá Government and SINOVAC have formulated a 10-year development plan and will establish a vaccine production base which can produce multiple types of vaccines through technical cooperation."We will carry out project construction and personnel training in accordance with the most advanced international standards, in order to achieve localized production of vaccines in Colombia as soon as possible. We firmly believe that this project will benefit the people of Colombia."

Mayor López highlighted the collaboration's importance, emphasizing its contribution to scientific progress and independence in producing essential vaccines: "Thanks to the Chinese government and Sinovac for having trusted in Bogota, for believing in us and in Colombia. Thank you Mr. Yin for being here with us with your team. BogotáBio is a wonderful legacy that we leave to Colombia in terms of sanitary sovereignty".

BogotáBio: An Innovation and Progress Platform for Colombia

On May 31, 2023, following a rigorous selection process, Sinovac was appointed as the strategic partner for the District of Bogotá. This enterprise will not only manufacture vaccines against hepatitis A, varicella, and polio but will also develop capacities for future vaccines, preparing the country for forthcoming health emergencies, generating employment, and nurturing Colombian scientific talent.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.